Actelion promotes brain haemorrhage drug

Swiss biotech firm Actelion is using Packer Forbes Communications to handle global work for a pre-launch product that prevents a tightening of the arteries in the brain following a haemorrhage.

Clazosentan, currently in late-stage trials, has been shown to cut the number and severity of cases of vasospasm following what is known as aneurismal subarachnoid haemorrhage (aSAH). It could become available by 2007.

Packer Forbes MD Alexa Forbes said: 'We aim to raise awareness among potential prescribers and medical media of the importance of preventing vasospasm following aSAH. We also want to start dialogue with patient support groups.'

The agency reports to Actelion's Basle-based global product communications manager Alan Archer, who previously worked at GCI Healthcare.

Packer Forbes bagged its first deal with Actelion eight months ago when it landed a UK contract for its Tracleer brand (PRWeek, 25 March). It also handles global work for Tracleer.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.